Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).

Edoardo Francini,Fang Shu Ou,Justin Rhoades,Eric Wolfe,Edward P. O’Connor,Gavin Ha,Gydush Gregory,Kaitlin Kelleher,Rupal S. Bhatt,Steven P. Balk,Christopher Sweeney,Viktor A. Adalsteinsson,Mary-Ellen Taplin,Atish D. Choudhury

Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).

2020

Edoardo Francini
Fang Shu Ou
Justin Rhoades
Eric Wolfe
Edward P. O’Connor
Gavin Ha
Gydush Gregory
Kaitlin Kelleher
Rupal S. Bhatt
Steven P. Balk
Christopher Sweeney
Viktor A. Adalsteinsson
Mary-Ellen Taplin
Atish D. Choudhury

174Background: Docetaxel (D) and cabazitaxel (C) are standard chemotherapies for mCRPC. A reliable biomarker predictive of resistance to D or C is yet to be identified. We aimed to assess the assoc...

Keywords:

Prostate cancer
Circulating free DNA
Biomarker (medicine)
Cancer research
Pathology
Castration
Medicine
Taxane
castration resistant
Docetaxel
Internal medicine
Oncology
taxane resistance
Cabazitaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations